• 1
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 2
    Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 88693.
  • 3
    Forejtova S, Mann H, Stolfa J, Vedral K, Fenclova I, Nemethova D, et al. Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol 2008; 27: 100513.
  • 4
    Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 16778.
  • 5
    Disease Activity Score in rheumatoid arthritis. 2010. URL:
  • 6
    Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S1008.
  • 7
    Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. The elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009; 68: 16805.
  • 8
    Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005; 32: 24105.
  • 9
    Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 278492.
  • 10
    Sajid MS, Tonsi A, Baig MK. Health-related quality of life measurement. Int J Health Care Qual Assur 2008; 21: 36573.
  • 11
    Ariza-Ariza R, Hernandez-Cruz B, Carmona L, Ruiz-Montesinos MD, Ballina J, Navarro-Sarabia F, and the Costs and Quality of Life in Rheumatoid Arthritis Study Group. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum 2006; 55: 7516.
  • 12
    The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199208.
  • 13
    Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36: 5519.
  • 14
    Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 5372.
  • 15
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 27192.
  • 16
    Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications [review]. Health Qual Life Outcomes 2003; 1: 54.
  • 17
    Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008; 35: 592602.
  • 18
    Burstrom K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006; 76: 35970.
  • 19
    Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095108.
  • 20
    Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D (corrected) RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 152837.
  • 21
    Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006; 22: 23541.
  • 22
    Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in Southern Sweden. Ann Rheum Dis 2010; 69: 3527.
  • 23
    Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in Southern Sweden. Ann Rheum Dis 2002; 61: 7938.
  • 24
    Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 115961.
  • 25
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 26
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 3618.
  • 27
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 121827.
  • 28
    Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK population survey. York (UK): Centre for Health Economics, University of York; 1995.
  • 29
    Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in Southern Sweden. Ann Rheum Dis 2004; 63: 410.
  • 30
    Kobelt G, Lindgren P, Geborek P. Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scand J Rheumatol 2009; 38: 40918.
  • 31
    Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis: a 7-year follow-up of 1839 patients in Southern Sweden. Ann Rheum Dis 2008; 67: 3742.
  • 32
    Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in Southern Sweden. Arthritis Rheum 2006; 54: 6006.
  • 33
    Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis: results from a six-year observational study in Southern Sweden. Arthritis Res Ther 2006; 8: R174.
  • 34
    Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol 2009; 36: 14218.
  • 35
    Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, et al. The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease: a UK collaborative study. The REFLUX trial. Health Technol Assess 2008; 12: 1181, iii–iv.
  • 36
    Jansson KA, Nemeth G, Granath F, Jonsson B, Blomqvist P. Health-related quality of life in patients before and after surgery for a herniated lumbar disc. J Bone Joint Surg Br 2005; 87: 95964.
  • 37
    Taylor M, Scuffham PA, Chaplin S, Papo NL. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. Value Health 2009; 12: 45965.
  • 38
    McHugh ML. Scientific inquiry: clinical statistics for primary care practitioners. Part II: absolute risk reduction, relative risk, relative risk reduction, and number needed to treat. J Spec Pediatr Nurs 2008; 13: 1358.
  • 39
    Lacey LA, Wolf A, O'Shea D, Erny S, Ruof J. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland. Int J Obes (Lond) 2005; 29: 97582.
  • 40
    Nan L, Johnson JA, Shaw JW, Coons SJ. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Med Decis Making 2007; 27: 3216.
  • 41
    Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007; 27: 32734.
  • 42
    Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005; 60: 157182.